Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dimetacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.47 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.47 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.47 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.47 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.47 |
| ▸ | OPRM1 known ✓ | P35372 | 5/20 | 0.47 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.47 |
| ▸ | CHRM4 known ✓ | P08173 | 4/20 | 0.47 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.47 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.47 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.47 |
| ▸ | OPRK1 known ✓ | P41145 | 4/20 | 0.47 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.47 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.47 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.47 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.47 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.42 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimetacrine SCHEMBL3501515 | 1.00 | CYP2D6 (0.75) | CYP2D6CYP1A2KMT2ALMNAMAPT | |
| Dimetacrine SCHEMBL29578094 | 0.87 | CYP2D6 (1.00) | CYP2D6CYP1A2KMT2ALMNAMAPT | |
| Dimetacrine SCHEMBL50120 | 0.87 | CYP2D6 (1.00) | CYP2D6CYP1A2KMT2ALMNAMAPT | |
| SCHEMBL11640552 | 0.79 | CYP2D6 (0.78) | CYP2D6CYP1A2KMT2ALMNAMAPT | |
| Dimetacrine SCHEMBL28221926 | 0.73 | HRH1 (0.71) | CYP2D6CYP1A2KMT2ALMNAMAPT | |
| SCHEMBL13231573 | 0.71 | KMT2A (0.68) | CYP2D6CYP1A2KMT2ALMNAMAPT | |
| SCHEMBL17739604 | 0.70 | KMT2A (0.68) | CYP2D6CYP1A2KMT2ALMNAMAPT | |
| SCHEMBL11640659 | 0.70 | KMT2A (0.63) | CYP2D6CYP1A2KMT2ALMNAMAPT | |
| Imipramine SCHEMBL20644144 | 0.69 | SLC6A4 (0.83) | CYP2D6CYP1A2KMT2ALMNAMAPT | |
| SCHEMBL21027093 | 0.69 | TP53 (0.51) | CYP2D6CYP1A2KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307386-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-09-19 | — | — | US | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| EP-3801527-A1 | NOVEL METHODS | Intra-Cellular Therapies, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| US-20210060009-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2021-03-04 | — | — | US | claimed |
| EP-3765021-A1 | NOVEL METHODS | Intra-Cellular Therapies, Inc. (US) | 2021-01-20 | — | — | EP | claimed |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | ENTERIN, INC. (US) | 2020-02-06 | — | — | US | claimed |
| WO-2019178484-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | claimed |
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | ENTERIN, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260053748-A1 | NOVEL METHODS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260041667-A1 | PRESCRIPTION DIGITAL THERAPEUTICS | BECKLEY PSYTECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260035334-A1 | METHOD OF SYNTHESIS | BECKLEY PSYTECH LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-12533355-B2 | Methods of treatment comprising administering lumateperone mono-tosylate capsules | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12503485-B2 | Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same | ENTERIN, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| WO-2012148799-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120277249-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | GREENJAY THERAPEUTICS, INC. | 2012-11-01 | — | — | US | disclosed |
| WO-2012129082-A1 | TREATMENTS TARGETING GAMMA-SYNUCLEIN EXPRESSION LEVELS | GEORGETOWN UNIVERSITY (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533355-B2 | Methods of treatment comprising administering lumateperone mono-tosylate capsules | HTR2C, SLC6A4, SLC6A2 | HRH1 1111/4885CHRM2 1302/4885CHRM1 2143/4885 |
| US-20210060009-A1 | NOVEL METHODS | HTR2A, HTR3B, HTR1A | HRH1 293/4885CHRM2 1975/4885CHRM1 2338/4885 |
| US-20200038420-A1 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | HSD17B7, CYP17A1, HSD17B2 | HRH1 3183/4885CHRM2 1172/4885CHRM1 1373/4885 |
| US-20260053748-A1 | NOVEL METHODS | HTR1D, HTR2C, HTR1A | HRH1 71/4885CHRM2 73/4885CHRM1 126/4885 |
| US-20240307386-A1 | NOVEL METHODS | OPRL1, HTR2A, OPRM1 | HRH1 701/4885CHRM2 1079/4885CHRM1 1174/4885 |
| US-20260035334-A1 | METHOD OF SYNTHESIS | HTR5A, HTR1A, HTR2C | HRH1 1041/4885CHRM2 556/4885CHRM1 317/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | HRH1 255/4885CHRM2 121/4885CHRM1 169/4885 |
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | HSD3B1, HSD3B2, HSD11B1 | HRH1 1090/4885CHRM2 2348/4885CHRM1 2360/4885 |
| US-20260041667-A1 | PRESCRIPTION DIGITAL THERAPEUTICS | HTR5A, PNMT, NPY5R | HRH1 1667/4885CHRM2 1752/4885CHRM1 935/4885 |
| US-12503485-B2 | Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same | CYP17A1, HSD17B13, HSD17B7 | HRH1 4514/4885CHRM2 4742/4885CHRM1 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.